BREAKING:🇺🇸 NASDAQ-LISTED COSMOS HEALTH SECURES $300 MILLION FINANCING TO LAUNCH ETHEREUM TREASURY STRATEGY.EVERYONE WANTS TO BUY $ETH NOW. ...

CHICAGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, announced today that it has entered into a securities purchase agreement with a U.S.-based institutional investor for the issuance of up to $300 million in senior secured convertible promissory notes (the “Facility”), subject to the satisfaction or waiver of certain conditions, to support the launch of its Ethereum (ETH) digital asset t ...

Core Insights - Cosmos Health Inc. has announced its entry into the U.S. market and the launch of U.S.-based manufacturing through a strategic agreement with DolCas Biotech LLC [1][2] - The production will take place in GMP-certified facilities, enhancing operational control and reducing tariff exposure [2][4] - This partnership aims to strengthen Cosmos Health's position in the premium nutraceuticals market and expand its portfolio with scientifically backed ingredients [3][4] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, owning proprietary pharmaceutical and nutraceutical brands and operating a telehealth platform [6] - The company has established R&D partnerships targeting major health disorders and focuses on innovative product development [6] - Cosmos Health has a global distribution platform and is expanding throughout Europe, Asia, and North America [6] Partnership Details - The agreement with DolCas Biotech is expected to leverage DolCas's expertise in clinically validated formulations and vertically integrated manufacturing [3][4] - DolCas Biotech is recognized for its commitment to quality and innovation, with a portfolio that includes clinically supported nutraceutical products [5] - The partnership is seen as a strategic move to support Cosmos Health's growth in the U.S. and globally [4]

Core Viewpoint - Cosmos Health Inc. reported a strong financial performance for Q1 2025, showcasing a significant turnaround with improved profitability metrics and disciplined cost management. Financial Highlights - Revenue for Q1 2025 was $13.71 million, a decrease of 5.98% from $14.58 million in Q1 2024, attributed to a strategic shift towards higher-margin areas [6] - Gross profit increased by 53.70% to $2.05 million from $1.33 million in the prior-year period, driven by an improved product mix [6] - Adjusted EBITDA rose by 157.8% to $0.37 million compared to a loss of $0.64 million in Q1 2024 [6] - Adjusted Net Income improved by 139.4% to $0.28 million, versus a loss of $0.71 million in the prior-year period [6] Profitability and Cost Management - The company achieved profitability on an adjusted basis for both EBITDA and Net Income, reflecting improved gross profitability and effective cost management [3][9] - Total operating expenses declined by 9.05% to $2.88 million, with significant reductions in salaries and wages (17.34%) and sales and marketing expenses (83.78%) [6] Balance Sheet and Cash Flow - Stockholders' equity increased by $1.42 million, with a liabilities-to-assets ratio of 54.6%, indicating financial discipline [5] - Total assets rose by 5.3% to $57.2 million, while total liabilities increased by 4.9% to $31.24 million [7] - Operating cash burn improved by 94.5% year-over-year, decreasing to negative $0.19 million from negative $3.41 million in Q1 2024 [8] Operational Developments - The wholesale logistics segment (CosmoFarm) and the nutraceutical and pharmaceutical products portfolio, including Sky Premium Life®, were key contributors to the strong performance [4] - The company is advancing its R&D pipeline, with projects like the CCX0722 weight management solution nearing launch [11] - Cosmos Health is expanding its high-margin contract manufacturing segment and growing its flagship nutraceutical brand, Sky Premium Life, in global markets [11]

Core Insights - Cosmos Health Inc. reported solid financial results for Q1 2025, showing a significant increase in gross profit and a positive turnaround in both Adjusted EBITDA and Adjusted Net Income [2][3][9] Financial Performance - Revenue for Q1 2025 was $13.71 million, a decrease of 5.98% from $14.58 million in Q1 2024, due to a strategic shift towards higher-margin areas [6] - Gross profit increased by 53.70% to $2.05 million, up from $1.33 million in the prior-year period, driven by an improved product mix and operational leverage [6] - Adjusted EBITDA rose by 157.8% to $0.37 million, compared to a loss of $0.64 million in Q1 2024 [6] - Adjusted Net Income improved by 139.4% to $0.28 million, versus a loss of $0.71 million in the prior-year period [6] Cost Management - Total operating expenses declined by 9.05% to $2.88 million, compared to $3.17 million in Q1 2024, attributed to a 17.34% reduction in salaries and wages and an 83.78% decline in sales and marketing expenses [6] - The company achieved a net loss of $0.82 million, narrowing by 56.17% from $1.87 million in the prior-year period [6] Balance Sheet Strength - Stockholders' equity increased by $1.42 million, with a liabilities-to-assets ratio of 54.6%, indicating continued financial discipline [5][7] - Total assets rose by 5.3% to $57.2 million, while total liabilities increased by 4.9% to $31.24 million [7] Operational Developments - The wholesale logistics segment (CosmoFarm) and the owned nutraceutical and pharmaceutical products portfolio were key contributors to the improved performance [4] - The company is advancing its R&D pipeline, including the CCX0722 weight management solution, and expanding its high-margin contract manufacturing segment [11] Management Commentary - The CEO expressed satisfaction with the first-quarter performance, highlighting the significant increase in gross profit and margins, as well as the return to profitability [9][10]

Financial Performance - For the three months ended March 31, 2025, the company reported revenue of $13,712,528, a decrease from $14,584,473 in the same period of 2024, representing a decline of approximately 6%[254]. - The net loss for the three months ended March 31, 2025, was $818,097, an improvement from a net loss of $1,866,690 in the corresponding period in 2024, indicating a reduction of approximately 44%[254]. - Revenue for the three-month period ended March 31, 2025, decreased by approximately 5.98% compared to the same period in 2024, primarily due to unfavorable foreign exchange movements and a marginal decrease in sales from Cosmofarm SA[256]. - Gross profit for the three months ended March 31, 2025, was $2,049,799, representing an increase of 53.7% compared to the same period in 2024, driven by a favorable revenue composition[260]. - Total operating expenses decreased by $286,790, or approximately 9.05%, to $2,882,944 for the three-month period ended March 31, 2025, reflecting disciplined cost management[261]. - The Company reported a net loss of $818,097 for the period ended March 31, 2025, with positive working capital of $1,259,012 compared to a negative working capital of $296,193 as of December 31, 2024[273][268]. - Cash generated from financing activities increased to $560,862 for the three-month period ended March 31, 2025, compared to $206,942 during the same period in 2024, driven by lower debt repayments and new financing arrangements[271]. - The foreign currency translation adjustment improved to a gain of $1,031,268 for the three-month period ended March 31, 2025, compared to a loss of $599,276 in the prior year[265]. Strategic Acquisitions and Growth - The acquisition of Bikas is expected to increase annual revenue by more than $10 million and enhance gross margins due to economies of scale[251]. - The company completed the acquisition of Cloudscreen for a total purchase price of $637,080, which includes 280,000 shares of common stock and cash to be settled in 2024[252]. - The company signed a definitive agreement to acquire ZipDoctor Inc. for a total sum of $150,000, enhancing its telemedicine capabilities[248]. - The company has made several strategic acquisitions to enhance its manufacturing, marketing, and R&D capabilities, strengthening its core product technology infrastructure[285]. Product Development and Innovation - The company has created and developed proprietary branded nutraceutical products, with over 160 product codes, aiming for high growth opportunities in the nutraceutical market[232]. - Innovation efforts include accelerating R&D on IP-driven products like CCX0722 for obesity and CCDL24 for gastrointestinal disorders, alongside the acquisition of the AI-driven drug repurposing platform "Cloudscreen®"[293]. - The proprietary biocide C-Sept Pro 2% combines 76% Isopropyl Alcohol and 2% chlorhexidine digluconate, while C-Scrub Wash 4% CHG is approved by the WHO for human use[294]. - The company’s portfolio includes Melatonin Spray® for insomnia, Otikon™ ear drops for ear pain, and Bio-bebe® organic infant care products[295][296][297]. Market Expansion and Distribution - The company anticipates receiving orders of more than 500,000 units in the first year and in excess of 3,000,000 units over the next five years for its Sky Premium Life products in the UAE[246]. - The company has established a distribution network exceeding 1,500 pharmacies in Greece, supported by upgraded robotic systems for efficient operations[231]. - The company aims to expand its sales distribution networks in new regions such as the UAE and Eastern Europe while strengthening market share in core markets[293]. - The Company plans to expand its brand name products and evaluate acquisition targets to enhance distribution, including a significant exclusive distribution agreement in the UAE[277]. Financial Outlook and Concerns - The Company anticipates using cash from debt or equity financing to conduct business in the upcoming year, with substantial doubt existing about its ability to continue as a going concern[272][278]. - The company intends to allocate funds for working capital, R&D, and marketing, although actual expenditures may differ due to industry uncertainties[288]. - As of March 31, 2025, there were no off-balance sheet arrangements reported[300]. - The company has net operating loss carry-forwards applicable to future taxable income in the United States, with income tax liabilities in the UK and Greece[311]. Operational Efficiency - Cost of Goods Sold (COGS) decreased by $1,588,118 or approximately 11.99%, amounting to $11,662,729 for the three-month period ended March 31, 2025, due to a shift towards higher-margin product lines[257]. - Management's strategy includes enhancing manufacturing capacities and building a multinational network of wholesalers, distributors, and pharmacies to support growth[281]. - The company continues to execute its "Growth Strategy" focusing on high-margin segments and proprietary brands such as Sky Premium Life®, Mediterranation®, and C-Sept® / C-Scrub® with launches in new geographical regions[283].

Core Insights - Cosmos Health Inc. has received an additional purchase order for 80,000 units of its Sky Premium Life products from Pharmalink in the UAE, following a successful sell-out of an initial order of 130,000 units [1][2] - The company aims to exceed 3 million units in cumulative orders over the first five years, supported by its exclusive distribution agreement with Pharmalink [2] - CEO Greg Siok highlighted the strong momentum of Sky Premium Life nutraceuticals in the UAE, emphasizing the effectiveness of the partnership with Pharmalink [3] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, owning proprietary pharmaceutical and nutraceutical brands [3] - The company manufactures and distributes healthcare products, including pharmaceuticals, food supplements, and medical devices, through its subsidiary Cana Laboratories S.A., which is licensed under European Good Manufacturing Practices [3] - Cosmos Health is expanding its global distribution platform throughout Europe, Asia, and North America, with established offices and distribution centers in Greece and the UK [3]

Core Points - Cosmos Health Inc. has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share, now due by November 3, 2025 [1][3] - The company was initially notified on November 6, 2024, that it was not in compliance as its stock price had been below $1.00 for 30 consecutive business days [2] - Cosmos Health continues to meet all other Nasdaq listing requirements and intends to regain compliance within the new timeframe [3] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada [4] - The company owns proprietary pharmaceutical and nutraceutical brands and operates a telehealth platform through its acquisition of ZipDoctor, Inc. [4] - It manufactures and distributes healthcare products, including pharmaceuticals and food supplements, and has established R&D partnerships targeting major health disorders [4]

Core Insights - Baird Medical is participating in the COSM conference, which is a significant event for the otolaryngology community, aimed at advancing research and clinical education in head and neck surgery [1][2] Company Overview - Baird Medical specializes in minimally invasive diagnostics and treatments, focusing on surgical robotic systems and innovative surgical instruments [4] - The company is FDA 510(k)-certified and its solutions are utilized in over 30 prestigious hospitals and clinics in the United States, including Johns Hopkins Hospital and Columbia University Medical Center [4] - Baird Medical is a market leader in China for thyroid microwave ablation devices and is expanding its presence in over 20 countries worldwide [4] Strategic Engagement - The participation in COSM allows Baird Medical to engage with key opinion leaders, clinicians, and researchers, showcasing its portfolio of minimally invasive solutions [2][3] - The company aims to collaborate with healthcare professionals to explore innovative approaches and integrated care strategies to improve patient outcomes in otolaryngology [3]

Core Viewpoint - Cosmos Health Inc. has announced that its CEO, Greg Siokas, has significantly increased his ownership stake in the company by acquiring 1,466,764 common shares valued at $526,000, reflecting his confidence in the company's future prospects [1][2][3] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, focusing on innovative R&D and owning proprietary pharmaceutical and nutraceutical brands [5] - The company manufactures and distributes healthcare products and operates a telehealth platform, with a global distribution network expanding throughout Europe, Asia, and North America [5] Recent Transactions - Greg Siokas has invested over $1.3 million in the past five months, increasing his total ownership to 5,582,066 common shares, with a cumulative investment exceeding $18 million since the company's inception [2][3] Product and Service Offerings - Cosmos Health owns a portfolio of brands including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept®, and C-Scrub®, and manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices under European Good Manufacturing Practices [5] - The company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, utilizing artificial intelligence for drug repurposing and focusing on novel patented nutraceuticals and innovative OTC products [5]